Chinese Academy of

A compound glutamine capsule (internal code 2021615) is a small-molecule oral therapeutic in Phase 3 development sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences for the treatment of mucositis. Glutamine is an amino acid with established roles in mucosal barrier function and immune support. The sponsor is evaluating the compound in a clinical trial (NCT04988971) as of October 2021, the most recent disclosed milestone. The program represents a non-pharmacological approach to mucositis management, positioning glutamine supplementation as a potential adjunctive or standalone therapy. Regulatory status is limited to clinical trials in China; no approval or licensing partnerships have been disclosed. The competitive landscape includes both approved therapies (low-intensity laser) and multiple Phase 2–3 candidates from diverse mechanisms (small-molecule, monoclonal antibody, other modalities), indicating an active but fragmented market for mucositis interventions. Peak sales projections and mechanism-of-action details remain undisclosed.

Mucositis—inflammation of the oral and gastrointestinal mucosa—is a significant dose-limiting toxicity in cancer patients undergoing chemotherapy and/or radiotherapy, affecting quality of life, treatment adherence, and clinical outcomes. Current management relies on supportive care, topical agents, and emerging pharmacological interventions; an unmet need persists for effective, well-tolerated systemic therapies. Glutamine supplementation has biological plausibility as a mucosal-protective agent, given its role as a primary fuel for enterocytes and immune cells. The competitive field is fragmented: approved options (laser therapy, topical agents) have limited efficacy or accessibility; Phase 3 candidates include GC4419 (Galera Therapeutics), clonidine (Monopar), and multiple investigational agents from the sponsor institution. A successful Phase 3 outcome for this glutamine capsule could establish oral amino-acid supplementation as a standard-of-care adjunct, particularly in China and potentially in other Asian markets. Commercial significance depends on efficacy data, regulatory approval pathway, and market adoption relative to emerging small-molecule and biologic competitors.

Drug Class: Amino acid supplement (small-molecule modality)

Mechanism of Action: Not yet disclosed; presumed to support mucosal barrier integrity and immune function via glutamine's role as a metabolic substrate for enterocytes and lymphocytes.

Molecular Type/Modality: Small molecule

Route of Administration: Oral (capsule)

Target: Not yet disclosed

Related Therapies: Glutamine is a naturally occurring amino acid; related investigational approaches include glutamine combined with thalidomide (same sponsor, Phase 3). Approved supportive agents for mucositis include topical rinses, low-intensity laser, and steroid sprays.

First Approval: Not yet approved; clinical-trial stage only

Patent Status: Not yet disclosed

China (NMPA): The compound is in clinical trials; regulatory status is 'clinical_trials' per the facts. No approval, conditional approval, or expedited designation has been disclosed.

FDA (United States): Not yet disclosed; no indication of US regulatory engagement or IND status.

EMA (European Union): Not yet disclosed.

PMDA (Japan): Not yet disclosed.

Approval History: None; the program remains investigational.

Expected LOE (Loss of Exclusivity) Date: Not yet disclosed.

Strategic Positioning: Xiyuan Hospital's multi-pronged approach—testing glutamine alone, glutamine plus thalidomide, spirulina derivatives, and steroid sprays in parallel—suggests a portfolio strategy to identify the most effective modality for mucositis. This approach mitigates single-program risk but may dilute resources and regulatory focus.

Competitive Implications: The glutamine capsule faces headwinds from GC4419 (Galera), which has demonstrated clinical efficacy in Phase 3 and is further advanced in development. Clonidine (Monopar) offers a novel mechanism (α2-adrenergic agonist) with potential differentiation. Glutamine's mechanism—if based on nutritional supplementation alone—may struggle to demonstrate superiority over placebo or active comparators without compelling efficacy data.

Regulatory Path: Approval is likely to be sought first in China (NMPA), given the sponsor's location and trial infrastructure. International expansion would require additional trials and regulatory submissions; no partnership or licensing strategy has been disclosed.

Future Catalysts: Phase 3 efficacy and safety data readout; regulatory submission to NMPA; potential partnership or licensing announcements; comparative efficacy analyses versus GC4419 or clonidine if head-to-head trials are conducted.

Expected Milestones: Next milestone date and label not yet disclosed; typical Phase 3 timelines suggest data availability within 2–4 years from October 2021, though no guidance has been provided.